CanSino vaccine phase 1 data - 108 healthy patients, three dose groups, results were neutralizing antibody and T-cell responses through 28 days, w/ dose dependent, about 50-80% mild-moderate adverse effects including injection site pain, fever, and fatigue. High dose will not be taken to phase 2 due to 17% Grade 3 AEs. No patients over 60 y/o. No data on longer-term response. Some pts had pre-existing antibodies to the viral vector used, a hindrance. Unknown what level of antibody/T-cell response is needed to protect from infection in human (they have only animal data on protective effect, so far). Phase 2 starting.
https://marlin-prod.literatumonline.com/pb-assets/Lancet/pdfs/S0140673620312083.pdf
More: Some reactions to this are “underwhelm” due to the antibody to vector problem, the modest SARS-CoV-2 antibody titer level achieved, and the discontinuation of the high dose.